A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

NCT01708174 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Medulloblastoma

Interventions

DRUG: LDE225
DRUG: TMZ

Sponsor

Novartis Pharmaceuticals